Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: Updated experience with 20 cases

Leukemia and Lymphoma

Volumn 21, Issue 5-6, 1996, Pages 429-435

  Meloni, Giovanna ^a   Vignetti, Marco ^a   Andrizzi, Cristina ^a   Capria, Saveria ^a   Foa, Robin ^b   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Department of Biomedical Sciences and Human Oncology ^*  (Italy)

Author keywords

Advanced AML; IL 2; Immunotherapy

Indexed keywords

INTERLEUKIN 2; LEUFERON; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DYSPNEA; FEMALE; FEVER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; OLIGURIA; PAIN; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; SCHOOL CHILD; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

EID: 0029866914     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609093440     Document Type: Article

References (20)

1. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Maory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Selpp, C. A., Simpson, C., Reichert, C. M. (1985) Observations of the sistemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med., 313, 1485-1492.
2. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Leitman, S., Leitman, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., White, D. E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Eng. J. Med., 316, 889-905.
3. West, W. H., Toner, K. W., Yannelli, J. R., Marshall, G. D., Orr, D. W., Thurman, G. B., Oldham, R. K. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Eng. J. Med., 316, 898-905.
4. Oshimi, K., Oshimi, Y., Akutsu, N. (1986) Cytotoxicity of IL-2-activated lymphocytes for leukemia and lymphoma cells. Blood, 68, 938-948.
5. Lotzova, E., Savary, C. A., Herberman, R. B. (1987) Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk. Res., 11, 1059-1066.
6. Fierro, M. T., Liao, X. S., Lusso, P., Bonferroni, M., Matera, L., Cesano, A., Lista, P., Arione, R., Forni, G., Foa, R. (1988) In vitro and in vivo susceptibility of human leukemic cells to LAK activity. Leukemia, 2, 50-54.
7. Adler, A., Chevernick, P. A., Whiteside, T. L., Lotzova, E., Herberman, R. B. (1988) Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and BM of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood, 71, 709-716.
8. Maraninchi, D., Blaise, D., Viens, P., Brandely, M., Olive, D., Lopez, M., Sainty, D., Marit, G., Stoppa, A. M., Reiffers, J., Gratecos, N., Bertau-Perez, P., Mannoni, P., Mawas, C., Hercend, T., Sebahoun, G., Carcassonne, Y. (1991) High-dose recombinant interleukin-2 and acute myeloid leukaemias in relapse. Blood, 78, 2182-2187.
9. Foa, R., Fierro, M. T., Tosti, S., Meloni, G., Gavosto, F., Mandelli, F. (1990) Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant Interleukin-2. Leuk. Lymph., 1, 113-117.
10. Foa, R., Meloni, G., Tosti, S., Novarino, A., Fenu, S., Gavosto, F., Mandelli, F. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: A pilot study. Br. J. Haematol., 77, 491-496.
11. Meloni, G., Foa, R., Capria, S., Tosti, S., Vignetti, M., Gavosto, F., Mandelli, F. (1990) IL-2 for the treatment of acute leukaemias. Leukemia, 6, 28-30.
12. Meloni, G., Vignetti, M., Foa, R. and Mandelli, F. (1994) Clinical studies with Interleukin-2 in patients with acute, myelogenous leukemia in different phases of disease. In Challenges of Modern Medicine, vol. 8: Cytokines: Basic Principles and Practical Applications, Eds S Romagnani, G Del Prete, AK Abbas, 287-292.
13. Foa, R., Guarini, A., Gillio Tos, A., Cardona, S., Fierro, M. T., Meloni, G., Tosti, S., Mandelli, F., Gavosto, F. (1991) Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukaemia patients treated with Interleukin-2: Evidence of in vivo lymphokine activated killer cell generation. Cancer Res., 51, 964-968.
14. Mandelli, F., Vignetti, M., Tosti, S., Andrizzi, C., Foa, R., Meloni, G. (1993) Interleukin 2 treatment in acute myelogenous leukemia. Stem Cells, 11, 263-268.
15. Meloni, G., Foa, R., Tosti, S., Vignetti, M., Mancini, F., Guarini, A., Marchis, D., Gavosto, F. and Mandelli, F. (1992) autologous bone marrow Transplantation followed by Interleukin-2 in children with advanced leukemia: a pilot study. Leukemia, 6, 780-785.
16. Fefer, A., Benyunes, M. C., Massumoto, C., Higuchi, C., York, A., Buckner, C. D., Thompson, J. A. (1993) Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Sem. Oncol., 20, 41-45.
17. Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Gillio Tos, A. and Mandelli, F. (1994) Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood, 84, 2158-2163.
18. Schomburg, A., Kirchner, H. and Atzpodien, J. (1993) Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens. Acta Haematol., 89, 119-131.
19. Foa, R. (1993) Does interleukin-2 have a role in the management of acute leukemia? J. Clin. Oncol., 11, 1817-1825.
20. Amadori, S., Arcese, W., Isacchi, G., Meloni, G., Petti, M. C., Monarca, B., Testi, A. M. and Mandelli, F. (1991) Mitoxantrone, etoposide and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J. Clin. Oncol., 9, 1210-1214.